【Good News】Haibu Pharmaceut←αical's Perindopril<ε  and Amlodipine Tablets (•€"‌Ⅲ) have been accepted by CDE.

Beijing Haibu Pharmaceutical Technolo∑× gy Co., Ltd. (referred t♥≥o as 'Haibu Pharmaceutical') was e&"→®stablished in 2005 and is a high-te↕​ch enterprise with 'chemical →¶ drug research and dγ§↑evelopment' as its core capability. It♦∏ ♣ has a research and development cent₩π↓er in Beijing, an active p↕♠φ<harmaceutical ingredient and form©§ulation pilot verification ce←♣nter, and a GMP industrial producti☆₩±πon base, mainly engaged in CR¥→O services for activ₽✔↔‌e pharmaceutical ingredient✔→©δs and formulations, MAH joint €♦β∞licensing, related a±←₩pplications for active pharmaceu​✘&tical ingredients, and commercial suppl¶ ¥'y of pharmaceutical intermediates.Haibu Pharmaceutical has rich experiencπ≈πe in the research and development t ♦✔ransfer, registratio​'n application, etc., of vari♠"ous dosage forms such as chemical raw₽≠ materials, oral solids, liquid pre₩₩£parations, sterile injections, external×φ₽× preparations. The R&D product₩☆"s cover multiple therapeΩ£₽δutic areas including anti-tu↑♠mor, anti-depression, anti-epi  ≠✔lepsy, anti-anxiety, cardiovasπ£®cular and cerebrovascular di→¥≥seases, digestive syβ≈αstem diseases, respi✘σratory system diseases.>">

Haibu Pharmaceuticalδ₽ has been awarded the title  ↑☆∑of 'Top 20 Chinese Pharm∏∑♠σaceutical R&D Compani&✘es' for several consecutive years £™ ≈and recognized as a 'Specialized &a₹$≥mp; Innovative Enterprise' inε¥π Beijing, a 'National High-tech E ₹nterprise', a 'Beijing Sc↔¶​ience and Technology Research Develo∏♠♦pment Institution', and a 'Beijing Yi<•zhuang Enterprise Innovati♠→on Center'.